MedTrace Logo

Treatment of Patellofemoral Osteoarthritis With Engineered Cartilage.

NCT06163573 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 75

Last updated 2026-03-24

No results posted yet for this study

Summary

The purpose of this investigator-initiated study is to assess the efficacy of treating patellofemoral osteoarthritis with an Advanced Therapy Medicinal Product (ATMP), autologous nasal chondrocyte tissue engineered cartilage (N-TEC), in comparison with a standard therapy using platelet rich plasma injections.

The engineered cartilage graft is obtained by culturing expanded autologous nasal chondrocytes within a collagen type I/III membrane.

Conditions

  • Patellofemoral Osteoarthritis

Interventions

BIOLOGICAL

N-TEC

Implantation of an autologous tissue engineered cartilage graft in the patellofemoral joint for treatment of osteoarthritis.

BIOLOGICAL

Platelet rich plasma

Injection of an autologous Conditioned Plasma ACP® on the basis of one injection per week for three consecutive weeks. Conditioned Plasma ACP®, Arthrex, one injection per week for three consecutive weeks.

Sponsors & Collaborators

  • Swiss National Science Foundation

    collaborator OTHER

  • Clinical Trial Unit, University Hospital Basel, Switzerland

    collaborator OTHER

  • University Hospital Wurzburg

    collaborator UNKNOWN

  • University Hospital, Basel, Switzerland

    lead OTHER

Principal Investigators

  • Marcus Mumme, Dr · University Hospital, Basel, Switzerland

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-06
Primary Completion
2028-09-30
Completion
2029-09-30

Countries

  • Croatia
  • Germany
  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06163573 on ClinicalTrials.gov